Last updated on February 2018

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)


Brief description of study

This study will assess the safety and immunogenicity of GARDASIL9 (V503) in 27- to 45-year-old women, and will complete the evaluation of GARDASIL9 in the extended age range of female participants for whom GARDASIL was proven to be effective. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 titers at 4 weeks postdose 3 are non-inferior in adult women as compared with titers in young adult women.

Clinical Study Identifier: NCT03158220

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 0002)
Graz, Austria
  Connect »

Study Coordinator

Klin. Abtlg. fuer Gynaekologie und Geburtshilfe ( Site 0001)
Wien, Austria
  Connect »

Study Coordinator

HUS Katiloopiston sairaala ( Site 0009)
Helsinki, Finland
  Connect »

Study Coordinator

Ita-Helsingin Rokotetutkimuskeskus ( Site 0011)
Helsinki, Finland
  Connect »

Study Coordinator

Porin Rokotetutkimusklinikka ( Site 0012)
Pori, Finland
  Connect »

Study Coordinator

Tampereen yliopisto - Tampereen rokotetutkimusklinikka ( Site 0010)
Tampere, Finland
  Connect »

Study Coordinator

Turun rokotetutkimusklinikka ( Site 0037)
Turku, Finland
  Connect »

Study Coordinator

Universitaetsmedizin Berlin Charite ( Site 0016)
Berlin, Germany
  Connect »

Study Coordinator

Universitaetsklinikum Duesseldorf ( Site 0014)
Dusseldorf, Germany
  Connect »

Study Coordinator

Praxis Dr. Peters ( Site 0015)
Hamburg, Germany
  Connect »

Study Coordinator

Universitaetsklinikum Hamburg-Eppendorf ( Site 0017)
Hamburg, Germany
  Connect »

Study Coordinator

Universitaetsklinikum Tuebingen ( Site 0013)
Tuebingen, Germany
  Connect »

Study Coordinator

Istituto Nazionale dei tumori ( Site 0020)
Milano, Italy
  Connect »

Study Coordinator

Ospedale San Raffaele ( Site 0022)
Milano, Italy
  Connect »

Study Coordinator

Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello ( Site 0023)
Palermo, Italy
  Connect »

Study Coordinator

CAP Centelles ( Site 0027)
Centelles, Spain
  Connect »

Study Coordinator

Institut Catala Oncologia de Bellvitge - ICO ( Site 0026)
Hospitalet de Llobregat, Spain
  Connect »

Study Coordinator

Hospital Sanitas La Moraleja ( Site 0031)
Madrid, Spain
  Connect »

Study Coordinator

Hospital Universitario Infanta Leonor ( Site 0028)
Madrid, Spain
  Connect »

Study Coordinator

Universitair Ziekenhuis Antwerpen ( Site 0007)
Edegem, Belgium
  Connect »

Study Coordinator

Universitair Ziekenhuis Gent ( Site 0006)
Gent, Belgium
  Connect »

Study Coordinator

Universitair Ziekenhuis Gasthuisberg ( Site 0005)
Leuven, Belgium
  Connect »

Study Coordinator

University of Antwerp ( Site 0004)
Wilrijk, Belgium
  Connect »

Study Coordinator

Complejo Hospitalario de Torrecardenas ( Site 0030)
Almeria, Spain
  Connect »